Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells

Experimental Eye Research

Volumn 93, Issue 4, 2011, Pages 442-451

  Tovar Vidales, Tara ^a   Clark, Abbot F ^a   Wordinger, Robert J ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Glaucoma; Tissue transglutaminase; Trabecular meshwork; Transforming growth factor 2

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

AGED; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLAUCOMA, OPEN-ANGLE; HUMANS; ISOQUINOLINES; PHOSPHORYLATION; PYRIDINES; PYRROLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRABECULAR MESHWORK; TRANSFORMING GROWTH FACTOR BETA2; TRANSGLUTAMINASES;

EID: 80055054064     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.06.011     Document Type: Article

References (51)

1. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 2000, 130:429-440. AGIS Investigators.
2. Bradley J.M., Vranka J., Colvis C.M., Conger D.M., Alexander J.P., Fisk A.S., Samples J.R., Acott T.S. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 1998, 39:2649-2658.
3. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 2004, 85:47-64.
4. Fleenor D.L., Shepard A.R., Hellberg P.E., Jacobson N., Pang I.H., Clark A.F. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 2006, 47:226-234.
5. Folk J.E., Finlayson J.S. The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem. 1977, 31:1-133.
6. Fuchshofer R., Birke M., Welge-Lussen U., Kook D., Lutjen-Drecoll E. Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest. Ophthalmol. Vis. Sci. 2005, 46:568-578.
7. Fuchshofer R., Welge-Lussen U., Lutjen-Drecoll E. The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system. Exp. Eye Res. 2003, 77:757-765.
8. Fuchshofer R., Yu A.H., Welge-Lussen U., Tamm E.R. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:715-726.
9. Gottanka J., Chan D., Eichhorn M., Lutjen-Drecoll E., Ethier C.R. Effects of TGF-beta2 in perfused human eyes. Invest. Ophthalmol. Vis. Sci. 2004, 45:153-158.
10. Inatani M., Tanihara H., Katsuta H., Honjo M., Kido N., Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:109-113.
11. Javelaud D., Mauviel A. Mammalian transforming growth factor-betas: smad signaling and physio-pathological roles. Int. J. Biochem. Cell Biol. 2004, 36:1161-1165.
12. Javelaud D., Mauviel A. Transforming growth factor-betas: smad signaling and roles in physiopathology. Pathol. Biol. (Paris) 2004, 52:50-54.
13. Javelaud D., Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005, 24:5742-5750.
14. Junglas B., Yu A.H., Welge-Lussen U., Tamm E.R., Fuchshofer R. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp. Eye Res. 2009, 88:1065-1075.
15. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Parrish R.K., Wilson M.R., Gordon M.O. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120:701-713. discussion 829-830.
16. Kim S.W., Lee Z.W., Lee C., Im K.S., Ha K.S. The role of tissue transglutaminase in the germinal vesicle breakdown of mouse oocytes. Biochem. Biophys. Res. Commun. 2001, 286:229-234.
17. Kobayashi T., Liu X., Wen F.Q., Fang Q., Abe S., Wang X.Q., Hashimoto M., Shen L., Kawasaki S., Kim H.J., Kohyama T., Rennard S.I. Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts. Biochem. Biophys. Res. Commun. 2005, 327:393-398.
18. Kojima S., Nara K., Rifkin D.B. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J. Cell Biol. 1993, 121:439-448.
19. Kojima S., Vernooy R., Moscatelli D., Amanuma H., Rifkin D.B. Lipo-polysaccharide inhibits activation of latent transforming growth factor-beta in bovine endothelial cells. J. Cell Physiol. 1995, 163:210-219.
20. Last J.A., Pan T., Ding Y., Reilly C., Keller K., Acott T.S., Fautsch M.P., Murphy C.J., Russell P. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 2011, 5:2147-2152.
21. Leask A., Abraham D.J. TGF-beta signaling and the fibrotic response. FASEB J. 2004, 18:816-827.
22. Lutjen-Drecoll E.R.J. Morphology of Aqueous Outflow Pathways in Normal and Glaucomatous Eyes. The Glaucomas 1996, 89-123. St. Louis: Mosby. R. Ritch, M.B. Shields, T. Krupin (Eds.).
23. Lutjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog. Retin. Eye Res. 1999, 18:91-119.
24. Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp. Eye Res. 2005, 81:1-4.
25. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67:753-791.
26. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1:169-178.
27. Massague J., Chen Y.G. Controlling TGF-beta signaling. Genes Dev. 2000, 14:627-644.
28. Nunes I., Gleizes P.E., Metz C.N., Rifkin D.B. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J. Cell Biol. 1997, 136:1151-1163.
29. Ochiai Y., Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn. J. Ophthalmol. 2002, 46:249-253.
30. Ozcan A.A., Ozdemir N., Canataroglu A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int. Ophthalmol. 2004, 25:19-22.
31. Pang I.H., Fleenor D.L., Hellberg P.E., Stropki K., McCartney M.D., Clark A.F. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest. Ophthalmol. Vis. Sci. 2003, 44:3502-3510.
32. Picht G., Welge-Luessen U., Grehn F., Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:199-207.
33. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 1996, 80:389-393.
34. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90:262-267.
35. Roberts A.B., Russo A., Felici A., Flanders K.C. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann. N. Y. Acad. Sci. 2003, 995:1-10.
36. Rohen J.W. Why is intraocular pressure elevated in chronic simple glaucoma? Anatomical considerations. Ophthalmology 1983, 90:758-765.
37. Rohen J.W., Lutjen-Drecoll E., Flugel C., Meyer M., Grierson I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye Res. 1993, 56:683-692.
38. Rohen J.W., Witmer R. Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 1972, 183:251-266.
39. Shepard A.R., Millar J.C., Pang I.H., Jacobson N., Wang W.H., Clark A.F. Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest. Ophthalmol. Vis. Sci. 2010, 51:2067-2076.
40. Tamm E.R., Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma?. Surv. Ophthalmol. 2007, 52:S101-S104.
41. Tomarev S.I., Wistow G., Raymond V., Dubois S., Malyukova I. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest. Ophthalmol. Vis. Sci. 2003, 44:2588-2596.
42. Tovar-Vidales T., Roque R., Clark A.F., Wordinger R.J. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues. Invest. Ophthalmol. Vis. Sci. 2008, 49:622-628.
43. Tripathi R.C., Li J., Chan W.F., Tripathi B.J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp. Eye Res. 1994, 59:723-727.
44. Tritschler I., Gramatzki D., Capper D., Mittelbronn M., Meyermann R., Saharinen J., Wolfgang W., Keski-Oja J., Weller M. Modulation of TGF-β activity by latent TGF-β-binding protein 1 in human malignant glioma cells. Int. J. Cancer 2009, 125:530-540.
45. Verrecchia F., Mauviel A. Transforming growth factor-beta signaling through the smad pathway: role in extracellular matrix gene expression and regulation. J. Invest. Dermatol. 2002, 118:211-215.
46. Welge-Lussen U., May C.A., Lutjen-Drecoll E. Induction of tissue transglutaminase in the trabecular meshwork by TGF-beta1 and TGF-beta2. Invest. Ophthalmol. Vis. Sci. 2000, 41:2229-2238.
47. Wordinger R.J., Clark A.F., Agarwal R., Lambert W., McNatt L., Wilson S.E., Qu Z., Fung B.K. Cultured human trabecular meshwork cells express functional growth factor receptors. Invest. Ophthalmol. Vis. Sci. 1998, 39:1575-1589.
48. Yue B.Y. The extracellular matrix and its modulation in the trabecular meshwork. Surv. Ophthalmol. 1996, 40:379-390.
49. Zhang J., Lesort M., Guttmann R.P., Johnson G.V. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 1998, 273:2288-2295.
50. Zhu H.J., Burgess A.W. Regulation of transforming growth factor-beta signaling. Mol. Cell Biol. Res. Commun. 2001, 4:321-330.
51. Zode G.S., Clark A.F., Wordinger R.J. Bone morphogenetic protein 4 inhibits TGF-beta2 stimulation of extracellular matrix proteins in optic nerve head cells: role of gremlin in ECM modulation. Glia 2009, 57:755-766.